Small Molecule innovator CDMO Market is Anticipated to Grow US$ 73.9 Bn By 2030

The global small molecule innovator CDMO market size was valued at USD 41.1 billion in 2020, and is predicted to be worth around USD 73.9 billion by 2030, registering a CAGR of 6.4% during the forecast period 2022 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39117

Small Molecule innovator CDMO Market Growth Factors

The COVID-19 pandemic has significantly impacted market growth. During this crisis, CDMOs are playing an important role in meeting the needs of pharmaceutical companies, biotech companies, and other end users. These have been working diligently towards the development of small-molecule drugs against SARS-CoV-2 since the end of 2019.

COVID-19 has caused a significant impact on the API CDMO market where China was a key performing country in contract manufacturing of APIs. In China, due to a strict government-imposed lockdown, 44 firms became non-operational and several governments chose to boycott APIs manufactured in China. To combat this shortage, several countries have started manufacturing their own APIs. COVID-19 has changed supply chains but has also boosted the API CDMO market. With the growing demand for outsourcing by pharma companies, CDMOs are now focusing more on continuous bioprocessing and process intensification.

There was unprecedented growth in 2020 due to the COVID-19 pandemic. The EFCG reported that around 80% of chemicals used to make drugs sold in Europe are supplied from India and China. The major factors fueling the growth of this market include increasing pharmaceutical R&D investment and the rising incidence of cancer and age-related disorders across the globe. Another factor fueling market growth is the growing demand for small molecule drugs. In 2020, small molecule drugs dominated new molecular entities (NMEs) approvals.

Small Molecule innovator CDMO Market Report Coverage

By Product Analysis

The small molecule API segment dominated the market and accounted for a revenue share of over 60.0% in 2021. This growth can primarily be attributed to the rising demand for small molecule innovators.

The small molecule drug product segment is expected to expand at a CAGR of 6.0% over the forecast period. The small molecule drug substances have become more complex, with manufacturing methods becoming more specialized.

By Stage Type Analysis

The clinical segment dominated the market in 2021 and held a revenue share of over 50.0%. The clinical phase represents the organization’s future, where mistakes can result in products not making it through the clinic or clinical programs being delayed, not to mention the impact on patients.

The commercial segment is projected to register the fastest growth rate of 7.2% over the forecast period. Rising demand for outsourcing by small- and medium-sized pharmaceutical companies is one of the factors driving the segment.

The labor paradigm that had previously serviced R&D activities will not work in the commercial space. This is where the role of CDMOs comes into play. CDMOs offer specialized expertise, time-saving, and cost-efficiency, which is likely to propel the segment growth during the forecast period.

By Customer Type Analysis

The pharmaceutical segment accounted for over 90.0% share of the global revenue in 2021. The biotechnology segment includes biotechnology firms. In these firms, the production of small molecules is also done.

The segment’s expansion is being fueled by factors such as rising biopharmaceutical demand and enhanced molecular efficiency. Furthermore, this growth can be attributed to large investments in the biotechnology and biopharmaceutical industries.

By Therapeutic Area Analysis

The oncology segment held the largest revenue share of over 40.0% in 2021 and is anticipated to register the fastest growth rate over the forecast period owing to the increasing number of cancer cases globally.

Increased government reimbursement policies and a rise in financing for the development of small molecule oncology therapies are other factors boosting the segment growth. In 2018, 42 NCEs were approved, and 38 in 2019 – a significant rise over the recent average of 25-35 NCE approvals per year.

The industry is also being driven by supportive government reimbursement policies and financing towards the development of small molecule oncology therapies. In addition, CDMOs are increasing their investments in facilities for the production of highly powerful APIs (HPAPIs).

By Regional Analysis

Asia Pacific accounted for the largest revenue share of over 40.0% in 2021. A key factor fueling the regional market growth is the significantly cheaper manufacturing costs than North America and Europe and favorable laws.

North America held the second-largest revenue share in 2021. It is one of the major contributors to the growth of the global market. It is characterized by the presence of several established pharmaceutical, biotechnology, and medical device companies.

Key Players

• Piramal Pharma Solutions
• Corden Pharma
• Wuxi AppTec
• Cambrex Corporation
• Recipharm AB
• Thermo Fisher Pantheon
• Lonza Group Ltd.
• Catalent Inc.
• Siegfried Holding AG
• Boehringer Ingelheim
• Covance Inc.

Market Segmentation

• By Product
  • Small Molecule API
  • Small Molecule Drug Product
    • Oral Solid Dose
    • Semi-Solid Dose
    • Liquid Dose
    • Others
• By Stage Type
  • Preclinical
  • Clinical
    • Phase I
      • Small
      • Medium
      • Large
    • Phase II
      • Small
      • Medium
      • Large
    • Phase III
      • Small
      • Medium
      • Large
  • Commercial
• By Customer Type
  • Pharmaceutical
    • Small
    • Medium
    • Large
  • Biotechnology
• By Therapeutic Area
  • Cardiovascular Diseases
  • Oncology
  • Respiratory Disorders
  • Neurology
  • Metabolic Disorders
  • Infectious Diseases
  • Others
• Regional
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • India
    • Japan
    • China
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players.

Click Here to View Full Report Table of Contents

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39117

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com